Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome

A new form of insulin-dependent diabetes has been recognised, occurring in patients with cancers who are treated with checkpoint inhibitors. Checkpoint inhibitors are monoclonal antibodies that block checkpoint molecules—such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1)—and have revolutionised cancer treatment because of their ability to improve survival in a growing number of cancers. 1 Ribas A Wolchok...